Evidence map›Paper›PMID 34132895›Full record

ArticleCancer chemotherapy and pharmacology2021

Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma.

Mikael Öman, Yvonne Wettergren, Elisabeth Odin, Sofia Westermark, Peter Naredi, Oskar Hemmingsson, Helena Taflin

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mikael ÖmanDepartment of Surgical and Perioperative Sciences, Surgery, Umeå University Faculty of Medicine, Umeå University, 90185, Umeå, Sweden. mikael.oman@surgery.umu.se.ORCID 0000-0002-0958-3236
Yvonne WettergrenDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital/Östra, 41345, Göteborg, Sweden.
Elisabeth OdinDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital/Östra, 41345, Göteborg, Sweden.
Sofia WestermarkDepartment of Surgical and Perioperative Sciences, Surgery, Umeå University Faculty of Medicine, Umeå University, 90185, Umeå, Sweden.
Peter NarediDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital/Östra, 41345, Göteborg, Sweden.
Oskar HemmingssonDepartment of Surgical and Perioperative Sciences, Surgery, Umeå University Faculty of Medicine, Umeå University, 90185, Umeå, Sweden.
Helena TaflinDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital/Östra, 41345, Göteborg, Sweden.
Sahlgrenska University Hospital · SEUmeå University · SEOrnsköldsvik Hospital · SE

Funding

Cancer Research Foundation in Umeå LP 11-1928Västerbotten Läns Landsting RV-216951Västerbotten Läns Landsting RV-764741Västerbotten Läns Landsting RV-864841
6 · The paper itself

Abstract

purposeThe aim was to investigate the pharmacokinetics of preoperatively administered intraperitoneal (IP) 5-FU in patients with resectable pancreatic ductal adenocarcinoma (PDAC) by analyzing levels of 5-FU and target metabolites in peritoneal fluid, plasma, liver, lymph nodes, pancreatic tumour, and pancreatic tissue. These results were correlated to expression of genes encoding enzymes of the 5-FU pathway and cell membrane transporters of 5-FU and FdUMP.

methodsTwenty-two patients with PDAC were treated with IP 5-FU before surgery. The postoperative treatment followed a routine clinical protocol. 5-FU and its metabolites were analyzed by LC-MS/MS. The expression of genes encoding enzymes and transporters in the 5-FU pathway was analyzed by qPCR.

resultsAfter IP treatment, 5-FU could be detected in plasma, lymph nodes, liver, pancreatic tumour, and pancreatic tissue. The highest 5-FU concentration was found in the liver, also expressing high levels of the 5-FU transporter OAT2. 5-FU was converted to active FdUMP in all tissues and the highest concentration was measured in lymph nodes, liver and pancreatic tumour (18.5, 6.1 and 6.7 pmol/g, respectively). There was a correlation between the FdUMP and dUr levels in lymph nodes (r = 0.70, p = 0.0076). In tumours, there was an association between OAT2 expression and FdUMP concentration.

conclusionThe study shows uptake of IP 5-FU and drug metabolism to active FdUMP in pancreatic tumour, liver, and lymph nodes. Extended studies are warranted to evaluate the IP route for 5-FU administration in PDAC patients.

Indexed as

AgedAntimetabolites, AntineoplasticCarcinoma, Pancreatic DuctalChromatography, LiquidCombined Modality TherapyFemaleFluorouracilHumansInjections, IntraperitonealMaleMiddle AgedPancreatic NeoplasmsPreoperative CareTandem Mass SpectrometryTissue DistributionAntimetabolites, AntineoplasticFluorouracil5-FluorouracilGene expressionIntraperitoneal chemotherapyPancreatic cancerPharmacokinetics

Identifiers

PMID34132895
PMCPMC8367903
OpenAlexW3170391519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.